Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of lcat in the preparation of medicines for treating and/or preventing hepatic bone disease

A technology of uses and drugs, applied in the directions of drug combinations, bone diseases, biochemical equipment and methods, etc., to achieve the effect of preventing and treating hepatic bone diseases, broadening the field of choice, and alleviating osteoporosis

Active Publication Date: 2020-03-24
NANJING UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report about LCAT in the treatment of hepatic bone disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of lcat in the preparation of medicines for treating and/or preventing hepatic bone disease
  • Use of lcat in the preparation of medicines for treating and/or preventing hepatic bone disease
  • Use of lcat in the preparation of medicines for treating and/or preventing hepatic bone disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1. Construction of primary osteoblast / primary osteoclast and primary liver parenchymal cells co-culture system

[0025] Implementation method: Add the isolated primary osteoblasts / primary osteoclasts into a microporous filter culture chamber (MerckMillipore, USA), add NBD fluorescently labeled cholesterol and incubate for 24 hours, then wash off the unphagocytosed cells with PBS solution. NBD fluorescently labeled cholesterol outside primary osteoblasts / primary osteoclasts. The primary hepatic parenchymal cells were transferred to the lower layer of the microporous membrane culture chamber. According to different treatments, the microporous membrane culture chamber system was divided into three groups, namely, PBS treatment group, exogenous rLCAT treatment group (100ng / ml), CCl4 pre-injured liver parenchymal cell group (1mM), and the treatment methods were as follows:

[0026] PBS treatment group: PBS solution was added to both the upper layer cells and the low...

Embodiment 2

[0031] Example 2. The expression of LCAT in mice with hepatic bone disease and the relationship between the expression of LCAT and bone mineral density in patients with hepatic bone disease

[0032]In order to verify the expression of LCAT in mice with hepatic bone disease and whether there is a certain relationship between the expression of LCAT and bone mineral density in patients with hepatic bone disease, we constructed a mouse model of hepatic bone disease and collected hepatic bone disease Patient serum and measured bone density data.

Embodiment approach

[0033] Implementation method: 1. Select 8-week-old female mice (C57BL / 6) and divide them into two groups, namely the hepatic bone disease group and the control group, with 6 mice in each group. The mice in the hepatic bone disease group were intraperitoneally injected with CCl for 46 weeks (the injection frequency was 2ul per gram of body weight every two days), and the mice in the control group were injected with olive oil (the injection frequency was the same as that of the hepatic bone disease group). After 6 weeks, the liver and serum of the two groups of mice were collected.

[0034] 2. The obtained hepatic bone disease model mouse liver was sectioned and then subjected to LCAT immunofluorescence staining. The LCAT protein was labeled with PE fluorescein, and the nuclear protein was labeled with DAPI, which showed red light and blue light under excitation light of 592nm and 358nm, respectively. 3. Select 8 slices for each group, take 10 pictures for each slice at 100x mag...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is a use of lecithin-cholesterol acyltransferase (LCAT) for preparing a drug or a healthcare product for treating and / or preventing hepatic bone disease.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the use of lecithin-cholesterol acyltransferase (LCAT) in the preparation of medicines for treating hepatic bone disease, osteoporosis or osteomalacia. Background technique [0002] As the metabolic center of the body, the liver is an important metabolic organ to maintain the body's homeostasis. A large number of liver cells not only undertake the function of digestion and detoxification, but also secrete a large number of cytokines. play an important regulatory role. Similarly, as another important organ of the human body—skeleton, in addition to exerting stress support and motor functions, it can also regulate the body's immunity through the secretion of regulatory factors, and regulate the body's homeostasis by affecting the body's glucose metabolism balance. At present, the regulation of liver to bone has been studied. Studies have found that the secretion of vitamin ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/45A61P19/08A61P19/10
CPCA23L33/00A23V2002/00A61K38/45C12Y203/01043A23V2200/306
Inventor 薛斌蒋青陆克石天舒
Owner NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com